Overview
This series examines pharmacist-integrated collaborative outpatient care across CKM risk management: how medication review, shared authority, patient feedback, and follow-up can change intermediate measures. Randomized evidence most consistently supports lower clinic systolic blood pressure; HbA1c improvement is favorable but heterogeneous and sensitive to study quality, while target-attainment results are sparse. The series then tests implementation and the bridge from risk-factor signals to cardiovascular or kidney events, which the supplied evidence does not establish.
Learning outcomes
- In three comparable randomized trials, the model was associated with a pooled 7.11 mm Hg lower clinic systolic blood pressure than usual care.
- HbA1c improvement is favorable but less certain because heterogeneity is substantial and the estimate weakens after excluding a high-risk trial.
- Target-attainment findings are directionally favorable but sparse, heterogeneous, and too imprecise to quantify clinical benefit.
- Clear authority, communication, patient feedback, and follow-up are part of the care model; better measurements do not prove fewer cardiovascular or kidney events.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
What makes pharmacist-integrated collaborative care a real care model?
It connects medication review, agreed treatment authority, patient information, communication, adherence support, and longitudinal follow-up around a shared plan. A pharmacist contact alone does not establish the same intervention.
What is the strongest evidence for pharmacist-integrated collaborative care?
The strongest result is a pooled 7.11 mm Hg lower clinic systolic blood pressure than usual care in three comparable adjusted trial estimates. The finding is coherent but does not guarantee the same effect in every program.
How certain is the evidence for HbA1c and target attainment?
The evidence is favorable in direction but not settled: HbA1c heterogeneity was substantial, the estimate weakened after excluding a high-risk trial, and target-attainment intervals were wide and based on sparse data.
Does better risk-factor control prove fewer cardiovascular or kidney events?
No; the supplied review does not directly establish fewer cardiovascular or kidney events. It mainly measured clinic systolic blood pressure and HbA1c, so event claims require direct, adequately powered, longer-term outcomes.